All In Biotech

Drug Trial Radar · NCT05890521

Safety Study of COVID19 Vaccine on the Market

Multi-center Safety Observation of COVID19 Vaccine in a Large Population

Last checked: Nov 19, 2026Latest source record: Jun 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

100,000

Planned (sponsor's estimate)

Start

Apr 2, 2022

Primary completion

Jun 16, 2022

Study completion Jun 2023

Sponsor

Sponsor type
Industry
Collaborators
Hunan Provincial Center for Disease Control and Prevention; Guizhou Center for Disease Control and Prevention; Hainan Center for Disease Control & Prevention
First posted
Jun 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Popular topic:Multi-center safety observation of recombinant Novel Coronavirus protein vaccine (CHO cells) in a large population Study population:People aged 18 and above

Conditions

  • COVID-19

Interventions

  • Recombinant new coronavirus vaccine (CHO cell)Biological

    Subjects who have not received any Novel Coronavirus vaccine or the full dose of recombinant Novel Coronavirus protein vaccine (CHO cells) shall receive 3 doses of the experimental vaccine intramuscular in the deltoid muscle of the upper arm or complete the remaining doses of the experimental vaccine as per the vaccination schedule at 0, 1, and 2 months, with a dose of 0.5ml for each person. Immunized subjects: intramuscular injection of one dose of the experimental vaccine into the deltoid muscle of the upper arm, 0.5ml for each person.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SAETime frame: The period from receipt of the first dose of vaccine to 1 year after receipt of the last dose
  2. AETime frame: The period from receipt of the first dose of vaccine to 1 year after receipt of the last dose
  3. AESITime frame: The period from receipt of the first dose of vaccine to 1 year after receipt of the last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hunan Provincial Center for Disease Control and Prevention

    Changsha, Hunan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.